Factors predicting response to hepatitis B vaccination in patients with inflammatory bowel disease

Vaccine

Volumn 31, Issue 30, 2013, Pages 3065-3071

  Sempere, Laura ^a   Almenta, Isabel ^a   Barrenengoa, Julio ^a   Gutiérrez, Ana ^a   Villanueva, Cesar O ^a   de Madaria, Enrique ^a   García, Vicente ^a   Sánchez Payá, José ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

Hepatitis B virus; Inflammatory bowel disease; Vaccination

Indexed keywords

ALBUMIN; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; HEPATITIS A HEPATITIS B VACCINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADOLESCENT; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DISEASE DURATION; ENTERITIS; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT OUTCOME; VACCINATION;

ADULT; COHORT STUDIES; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSION; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; VACCINATION; VACCINES, SYNTHETIC;

EID: 84878966475     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.04.059     Document Type: Article

References (39)

1. Maynard J.E. Hepatitis B: global importance and need for control. Vaccine 1990, 8(Suppl.):S18-S20. discussion S1-3.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97-107.
3. Szmuness W., Stevens C.E., Harley E.J., Zang E.A., Oleszko W.R., William D.C., et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980, 303:833-841.
4. Coates T., Wilson R., Patrick G., Andre F., Watson V. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther 2001, 23:392-403.
5. Hadler S.C., Margolis H.S. Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. Curr Clin Top Infect Dis 1992, 12:282-308.
6. Averhoff F., Mahoney F., Coleman P., Schatz G., Hurwitz E., Margolis H. Immunogenicity of hepatitis B vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998, 15:1-8.
7. Loras C., Gisbert J.P., Minguez M., Merino O., Bujanda L., Saro C., et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010, 59:1340-1346.
8. Loras C., Saro C., Gonzalez-Huix F., Mínguez M., Merino O., Gisbert J.P., et al. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009, 104:57-63.
9. Chevaux J.B., Nani A., Oussalah A., Venard V., Bensenane M., Belle A., et al. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis 2010, 16:916-924.
10. Rahier J.F., Ben-Horin S., Chowers Y., Conlon C., De Munter P., D'Haens G., et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009, 3:47-91.
11. Gisbert J.P., Chaparro M., Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011, 33:619-633.
12. Vida Perez L., Gomez Camacho F., Garcia Sanchez V., Iglesias Flores E.M., Castillo Molina L., Cerezo Ruiz A., et al. Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease. Med Clin (Barc) 2009, 132:331-335.
13. Altunoz M.E., Senates E., Yesil A., Calhan T., Ovunc A.O. Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. Dig Dis Sci 2012, 57:1039-1044.
14. Gisbert J.P., Villagrasa J.R., Rodriguez-Nogueiras A., Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 2012, 107:1460-1466.
15. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989, 170:2-6. discussion 16-9.
16. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(Suppl. A):5-36.
17. Biancone L., Michetti P., Travis S., Escher J.C., Moser G., Forbes A., et al. European evidence-based consensus on the management of ulcerative colitis: special situations. J Crohns Colitis 2008, 2:63-92.
18. Van Assche G., Dignass A., Reinisch W., van der Woude C.J., Sturm A., De Vos M., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010, 4:63-101.
19. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
20. Declaration of Helsinki World Medical Association. World Med J 2008, 54:120-124. Available from:. http://www.wma.net/.
21. Gisbert J.P., Menchen L., Garcia-Sanchez V., Marin I., Villagrasa J.R., Chaparro M. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012, 35:1379-1385.
22. Kugathasan S., Saubermann L.J., Smith L., Kou D., Itoh J., Binion D.G., et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007, 56:1696-1705.
23. Fiocchi C. Early versus late immune mediated inflammatory diseases. Acta Gastroenterol Belg 2011, 74:548-552.
24. Veny M., Esteller M., Ricart E., Pique J.M., Panes J., Salas A. Late Crohn's disease patients present an increase in peripheral Th17 cells and cytokine production compared with early patients. Aliment Pharmacol Ther 2010, 31:561-572.
25. Kardar G.A., Jeddi-Tehrani M., Shokri F. Diminished Th1 and Th2 cytokine production in healthy adult nonresponders to recombinant hepatitis B vaccine. Scand J Immunol 2002, 55:311-314.
26. de Rave S., Heijtink R.A., Bakker-Bendik M., Boot J., Schalm S.W. Immunogenicity of standard and low dose vaccination using yeast-derived recombinant hepatitis B surface antigen in elderly volunteers. Vaccine 1994, 12:532-534.
27. Faulk W.P., Edsall G. Vaccines and vaccination programs - special emphasis in malnutrition. Am J Clin Nutr 1978, 31:2237-2247.
28. Thung S.N., Gerber M.A. Specificities of albumin receptors and albumin antibodies. Infect Immun 1981, 32:1292-1294.
29. Fabrizi F., Dixit V., Martin P., Jadoul M., Messa P. Meta-analysis. The impact of nutritional status on the immune response to hepatitis B virus vaccine in chronic kidney disease. Dig Dis Sci 2012, 57:1366-1372.
30. Ashwell J.D., Lu F.W., Vacchio M.S. Glucocorticoids in T cell development and function. Annu Rev Immunol 2000, 18:309-345.
31. Posey W.C., Nelson H.S., Branch B., Pearlman D.S. The effects of acute corticosteroid therapy for asthma on serum immunoglobulin levels. J Allergy Clin Immunol 1978, 62:340-348.
32. Fedor M.E., Rubinstein A. Effects of long-term low-dose corticosteroid therapy on humoral immunity. Ann Allergy Asthma Immunol 2006, 97:113-116.
33. Herron A., Dettleff G., Hixon B., Brandwin L., Ortbals D., Hornick R., et al. Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. JAMA 1979, 242:53-56.
34. Aikawa N.E., Campos L.M., Silva C.A., Carvalho J.F., Saad C.G., Trudes G., et al. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol 2012, 39:167-173.
35. Lahood N., Emerson S.S., Kumar P., Sorensen R.U. Antibody levels and response to pneumococcal vaccine in steroid-dependent asthma. Ann Allergy 1993, 70:289-294.
36. Dotan I., Werner L., Vigodman S., Agarwal S., Pfeffer J., Horowitz N., et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis 2012, 18:261-268.
37. Kapetanovic M.C., Saxne T., Sjoholm A., Truedsson L., Jonsson G., Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:106-111.
38. Via C.S., Shustov A., Rus V., Lang T., Nguyen P., Finkelman F.D. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001, 167:6821-6826.
39. Souto-Carneiro M.M., Mahadevan V., Takada K., Fritsch-Stork R., Nanki T., Brown M., et al. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther 2009, 11:R84.